TY - JOUR
T1 - Gender differences in clinical outcomes after percutaneous coronary interventions with zotarolimus-eluting stents
T2 - Insights from the Korean endeavor registry
AU - Song, Pil Sang
AU - Song, Young Bin
AU - Hahn, Joo Yong
AU - Kim, Doo Il
AU - Yang, Jeong Hoon
AU - Choi, Seung Hyuk
AU - Choi, Jin Ho
AU - Gwon, Hyeon Cheol
AU - Park, Hun Sik
AU - Lee, Sahng
AU - Han, Kyoo Rok
AU - Rha, Seung Woon
AU - Cho, Byung Ryul
AU - Park, Jong Sun
AU - Yoon, Junghan
AU - Lim, Do Sun
PY - 2013/12
Y1 - 2013/12
N2 - BACKGROUND:: The impact of gender on outcomes after percutaneous coronary intervention (PCI) with second-generation drug-eluting stents is not known in Asian patients. The authors studied outcomes after PCI with zotarolimus-eluting stent in unselected consecutive series of Asian patients according to gender. METHODS:: Outcomes among patients treated with zotarolimus-eluting stents from multicenter registry were evaluated by gender. The primary outcome was major adverse cardiac events, composite of cardiac death, myocardial infarction and target lesion revascularization at 1 year. RESULTS:: Of 2,840 patients, 855 (30.1%) were women. Comparatively, women were older; more frequently had diabetes, hypertension, and dyslipidemia; less frequently women were current smokers, had previous myocardial infarctions and previous PCIs; were more likely to have culprit lesions in left anterior descending coronary artery; and underwent more multilesion PCIs. After adjustment for baseline differences, women were still at lower risk of major adverse cardiac events (38 [4.4%] versus 137 [6.9%], adjusted hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.30-0.89, P = 0.018), mainly driven by target lesion revascularization (24 [2.8%] versus 106 [5.3%], adjusted HR: 0.41, 95% CI: 0.24-0.70, P = 0.001) at 1 year, although rates of cardiac death, myocardial infarction and stent thrombosis were similar between genders. These results were consistent after propensity score-matched population analysis (for major adverse cardiac events, adjusted HR: 0.36, 95% CI: 0.18-0.69, P = 0.012; for target lesion revascularization, adjusted HR: 0.32, 95% CI: 0.15-0.69, P = 0.004) and were also constant among various high-risk subgroups. CONCLUSIONS:: Despite greater baseline clinical and angiographic risk, the use of the zotarolimus-eluting stent is associated with favorable outcomes among Asian women treated with PCI.
AB - BACKGROUND:: The impact of gender on outcomes after percutaneous coronary intervention (PCI) with second-generation drug-eluting stents is not known in Asian patients. The authors studied outcomes after PCI with zotarolimus-eluting stent in unselected consecutive series of Asian patients according to gender. METHODS:: Outcomes among patients treated with zotarolimus-eluting stents from multicenter registry were evaluated by gender. The primary outcome was major adverse cardiac events, composite of cardiac death, myocardial infarction and target lesion revascularization at 1 year. RESULTS:: Of 2,840 patients, 855 (30.1%) were women. Comparatively, women were older; more frequently had diabetes, hypertension, and dyslipidemia; less frequently women were current smokers, had previous myocardial infarctions and previous PCIs; were more likely to have culprit lesions in left anterior descending coronary artery; and underwent more multilesion PCIs. After adjustment for baseline differences, women were still at lower risk of major adverse cardiac events (38 [4.4%] versus 137 [6.9%], adjusted hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.30-0.89, P = 0.018), mainly driven by target lesion revascularization (24 [2.8%] versus 106 [5.3%], adjusted HR: 0.41, 95% CI: 0.24-0.70, P = 0.001) at 1 year, although rates of cardiac death, myocardial infarction and stent thrombosis were similar between genders. These results were consistent after propensity score-matched population analysis (for major adverse cardiac events, adjusted HR: 0.36, 95% CI: 0.18-0.69, P = 0.012; for target lesion revascularization, adjusted HR: 0.32, 95% CI: 0.15-0.69, P = 0.004) and were also constant among various high-risk subgroups. CONCLUSIONS:: Despite greater baseline clinical and angiographic risk, the use of the zotarolimus-eluting stent is associated with favorable outcomes among Asian women treated with PCI.
KW - Drug-eluting stent
KW - Gender
KW - Percutaneous transluminal coronary angioplasty
UR - https://www.scopus.com/pages/publications/84890857920
U2 - 10.1097/MAJ.0b013e318297bd98
DO - 10.1097/MAJ.0b013e318297bd98
M3 - Article
C2 - 23842205
AN - SCOPUS:84890857920
SN - 0002-9629
VL - 346
SP - 479
EP - 485
JO - American Journal of the Medical Sciences
JF - American Journal of the Medical Sciences
IS - 6
ER -
